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Bone morphogenetic proteins (BMPs) are an integral component of the TGFb superfamily, responsible for regulation of cell
proliferation, differentiation, migration and programmed cell death in a variety of cell types. The BMPs transduce their signals directly
through the SMAD family of proteins but they also have been reported to interact with the MAPK and Erk pathways. Inactivation of
the BMP pathway genes has been implicated as important in several cancers. Recent work has shown that BMP3b is epigenetically
inactivated in cancer and suggests that BMP6 can be epigenetically inactivated. We investigated whether BMP6 is epigenetically
inactivated in cell lines and whether BMP3b and BMP6 are epigenetically inactivated in non-small-cell lung cancer (NSCLC). We also
studied the relationship between BMP methylation and k-ras mutation. Here, we demonstrate that the BMP3b and BMP6 genes are
common targets of epigenetic inactivation in NSCLC, and that they are significantly more likely to be concurrently inactivated
(P¼0.009). Furthermore, this coinactivation of BMP3b and BMP6 is significantly associated with mutation of k-ras codon 12 in lung
cancer (P¼0.003); those with a k-ras mutation were six times more likely to have concurrent methylation of these BMP loci. Hence,
these data suggest that concurrent inactivation of the BMP and activation of the Ras signalling pathways are important in lung
carcinogenesis.
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k-ras mutation, which leads to aberrant Ras/MAP-K pro-growth
signalling, has been well studied in cancer (Cunningham and
Weinberg, 1985; Nelson et al, 1999; Huber and Stratakis, 2004).
However, additional signalling pathways are acknowledged to play
important roles in malignant disease, with the bone morphogenetic
protein (BMP) signalling pathway emerging as important in
multiple cancers (Nagatake et al, 1996; Tamada et al, 2001; Baldus
et al, 2004; Dai et al, 2004; Kim et al, 2004). It is well recognised
that the BMP signalling pathways are crucial for all stages of
embryonic development, including regulation of lung development
and airway branching (Weaver et al, 1999; Lu et al, 2001;
Rosendahl et al, 2002). The BMPs have been shown to be growth
inhibitory by suppressing proliferation (Dai et al, 2004; Haudens-
child et al, 2004). They act through upregulation of the cell cycle
proteins p21 and p27 (Nakamura et al, 2003; Brubaker et al, 2004;
Haudenschild et al, 2004). The relationship between the TGFb/
BMP antigrowth and Ras/MAP-K progrowth signalling pathways
remains unclear, but there is recent evidence of crosstalk between
them (Kretzschmar et al, 1997; Yue et al, 1999; Wach et al, 2001).
While BMP-2 stimulation of osteoblasts leads to activation of Ras
(Nakayama et al, 2003), in Xenopus, BMP-4-stimulated erythroid
differentiation is inhibited by dominant-negative activation of the
Ras pathway (Xu et al, 1996). SMAD7, one of the inhibitory
SMADs of the BMP/TGFb signalling pathway, has been shown to
cooperate with oncogenic Ras to escape growth arrest (Liu et al,
2003). While there is experimental evidence of an association
between the BMP signalling proteins and oncogenic Ras, the
nature of any interaction of BMP cytokine inactivation and k-ras
mutation has been relatively unexplored in human tumours. As a
result of the known importance of BMP signalling in the
respiratory tract and the in vitro evidence of crosstalk between
signalling pathways, we hypothesised that concurrent BMP
inactivation and oncogenic k-ras mutation would be important
in non-small-cell lung cancer (NSCLC).
MATERIALS AND METHODS
Study population
Eligible cases consisted of all the newly diagnosed patients with
resectable lung cancer who received treatment at the Massachu-
setts General Hospital Thoracic Surgery Service from November
1992 to December 1996 (Nelson et al, 1999). All patients involved
provided written informed consent in accordance with the
appropriate institutional review boards. Patients with recurrent
disease or nonoperable tumours were excluded. Tumours were
snap-frozen in liquid nitrogen and stored at  801C until genomic
preparation. There were 155 cases with fresh tumour DNA
available to be tested for BMP3b and BMP6 methylation.
Demographic and epidemiologic data, including all of the data
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son tobacco use and occupational asbestos exposure, were obtained
from a self-administered questionnaire completed by patients and
subsequently reviewed by a single reviewer during the hospitalisa-
tion for thoracic surgery. Asbestos exposure was defined as having
any occupational asbestos exposure (yes/no), assessed as pre-
viously described (Nelson et al, 1999).
Cell culture
Lymphoblastic WTK1 and HT cells, small-cell carcinoma Shp77
cells, and non-small-cell carcinoma H322M and A549 cells were
maintained in RPMI-1640 medium supplemented with 10% fetal
calf serum. Prostate carcinoma DU145 cells and lung fibroblast
IMR90 cells were maintained in minimum essential media
(Eagle’s) supplemented with 10% fetal calf serum. WTK1 cells
(2 10
5) in 10ml media were treated with 1ml 5-aza-deoxycyta-
dine in PBS or PBS alone for 3 days and then harvested.
Reverse transcription PCR
Total RNA was isolated using Qiagen RNeasy kit. cDNA was
synthesised from the RNA using the SuperScript III kit from
Invitrogen. Reverse transcription PCR (RT–PCR) amplification of
the BMP6 cDNA was performed using primers designed with
Primer3. The BMP6 primers used are as follows: 50-ACA GCA TAA
CAT GGG GCT TC-30 (sense) and 50-CTC GGG GTT CAT AAG
GTG AA-30. B-actin cDNA was amplified using primers supplied
with the SuperScript III kit. Approximately 50ng of DNA was used
as template. The PCR mixture contained 10  PCR buffer, dNTPs
(200mM of each), primers (1mM of each) and 0.25ml TaqGold.
cDNA was amplified using an annealing temperature of 601C over
35 cycles. PCR product was visualised on an ethidium bromide-
stained agarose gel.
Methylation-specific PCR
Two sets of primers specific to the BMP6 promoter region were
designed using Primer3 to amplify bisulphite-modified DNA; one
specific for DNA methylated (M) at the promoter region and the
other specific for unmethylated (U) DNA. The primers used are as
follows: (M) 50-GGT TTG TTG GGT AGT CGG G-30 (sense) and
GCC CCT CCC CAA ATC G-30 (antisense) and (U) 50-TTG GGT
AGT TGG GTG ATT GTT-30 (sense) and 50-ACA CCC CTC CCC
AAA TCA-30 (antisense). Approximately 50ng of sodium bisuph-
fite-modified DNA was used as template. The PCR mixture
contained 10  PCR buffer, dNTPs (200mM of each), primers
(1mM of each) and 0.25ml TaqGold. Product was amplified using an
annealing temperature of 601C over 38 cycles. Nontreated and SssI
methylase-treated lymphocytes were used as controls. PCR
products were separated by electrophoresis and visualised by
ethidium bromide staining.
Statistical analysis
SAS software was used for statistical analysis. Wilcoxon rank sum
test and Fisher’s exact test (or w
2 test) were used for continuous
and categorical variables in univariate analysis, respectively.
Multivariate logistic regression was conducted to estimate the
relationship between methylation of BMPs, k-ras mutation and
covariates that were statistically significant in univariate analysis
and that were important biologically.
RESULTS
Methylation of BMP6 in cell lines
In an effort to determine whether transcription of the BMP6 gene
is inhibited by promoter methylation, we first examined the
transcriptional status of BMP6 in cell lines using RT–PCR
(Figure 1A). BMP6 mRNA was absent in WTK1 normal human
lymphoblastoid cells. Following treatment with 5-aza-deoxycyta-
dine, a DNA methyltransferase inhibitor, transcription was
reactivated, demonstrating that the loss of transcription of BMP6
is due to epigenetic inactivation (Figure 1B). Using primers
designed specifically to differentiate between methylated and
nonmethylated DNA at the BMP6 gene promoter, we demonstrated
that the WTK1 cells are methylated at the BMP6 gene promoter
(Figure 1C).
Methylation of BMP3b and BMP6 in NSCLC cases
We evaluated BMP3b and BMP6 gene promoter methylation status
in 155 NSCLC cases. In a consecutive case series, we found that
57% (88 out of 155) and 43% (67 out of 155) of NSCLCs were
methylated at the BMP3b and BMP6 gene promoters, respectively.
Since both BMP3b and BMP6 signal in the same pathways, we
tested whether there was a relationship between inactivation of the
two genes. We found that 52% (46/88) of the cases with BMP3b
methylation were also positive for BMP6 methylation; 31% (21/67)
of cases without BMP3b methylation were positive for BMP6
methylation. This statistically significant association between
concurrent methylation of BMP3b and BMP6 (P¼0.009) indicates
that the epigenetic silencing of these genes does not occur
independently in lung cancer.
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Figure 1 BMP6 is epigenetically inactivated in cancer cell lines. (A) BMP6
cDNA was amplified using an annealing temperature of 601C over 35
cycles with the following primers: 50-ACA GCA TAA CAT GGG GCT TC-
30 (sense) and 50-CTC GGG GTT CAT AAG GTG AA-30 (antisense). The
WTK1 and HT cell lines did not express BMP6. (B) WTK1 cells were
treated with 1ml 5-aza-deoxycytadine in PBS or PBS alone for 3 days and
then harvested. BMP6 is re-expressed in the WTK1 cells. (C) The BMP6
gene promoter methylation status was determined by amplifying bisulphite-
modified DNA using primers specific to methylated (M) and unmethylated
(U) DNA. The DNA was amplified using an annealing temperature of 601C
over 38 cycles with the following primers: (M) 50-GGT TTG TTG GGT
AGT CGG G-30 (sense) and GCC CCT CCC CAA ATC G-30 (antisense)
and (U) 50-TTG GGT AGT TGG GTG ATT GTT-30 (sense) and 50-ACA
CCC CTC CCC AAA TCA-30 (antisense).
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mutation in NSCLC
We next investigated the relationship between BMP epigenetic
inactivation and k-ras mutation. We previously have reported the
k-ras mutation status of these cases (Nelson et al, 1999). In the
subset of cases with both k-ras and BMP data, 16% (24/147) were
mutated at codon 12 of the k-ras gene and BMP3b methylation was
significantly associated with k-ras mutation (Table 1, Po0.03).
Those with BMP6 methylation were more likely to have k-ras
mutation, but this was not statistically significant. However,
concurrent methylation of both BMP3b and BMP6 was strongly
associated with k-ras mutation (Table 1, Po0.003).
Concurrent BMP methylation, k-ras mutation, and tobacco
and asbestos exposure in NSCLC
k-ras mutation has previously been associated with asbestos
exposure in these patients (Nelson et al, 1999). In addition,
pulmonary interstitial fibrosis (a condition associated with
asbestos exposure) is associated with activation of the BMP/SMAD
signalling pathway (Matsuse et al, 1996; Rosendahl et al, 2002).
Therefore, we examined the relationship between tobacco use,
asbestos exposure and k-ras mutation, and epigenetic silencing of
the BMPs (Table 2). A logistic regression analysis, controlling for
histology and gender showed that tumours with k-ras mutation are
six-fold more likely to have concurrent BMP3/6 silencing
(OR¼6.0, 95% confidence interval (CI) ¼2.0–17.9) and asbestos
exposure significantly decreased the likelihood of concurrent
BMP3/6 methylation (OR¼0.2, CI 0.1–0.9; Table 2). There was no
statistically significant relationship between BMP methylation and
tobacco exposure (Table 2).
DISCUSSION
The BMPs are well recognised to play multiple crucial roles in the
development of diverse tissues. They are also believed to play a
role in the genesis of many tumour types, with their inactivation
allowing for dysregulated cellular proliferation. There are multiple
BMPs with overlapping substrate specificity (Stott et al, 1998). Our
data, showing that epigenetic inactivation of BMP3b (at a
frequency similar to that previously reported (Dai et al, 2004))
and BMP6 tend to occur together in lung cancer, suggests that in
NSCLC multiple BMPs may need to be silenced in order to
abrogate their antigrowth signalling.
Increasing evidence shows that there is a crosstalk between
TGFb/BMP antigrowth signalling and Ras/MAP-K progrowth
signalling, and it is likely that the interaction of these pathways
is cell type and tissue specific. Some evidence suggests that Ras
inactivates SMAD signalling while other evidence suggests that Ras
activates SMAD signalling (Kretzschmar et al, 1997; Yue et al,
1999). Further, inhibitory SMADs have been shown to be
upregulated in coordination with k-ras mutation in epithelial
cancer (Liu et al, 2003). Although the exact relationship between
BMPs and Ras in signalling are unclear, our data are consistent
with the mounting evidence that the relationship is important in
solid tumours.
The finding that asbestos exposure is associated with a
significantly different pattern of signalling dysregulation in NSCLC
supports the notion that clonal selection has important nodal
points that are influenced by the pattern of carcinogen exposure.
The current work suggests that the Ras and BMP pathways are part
of a complex network of inter-related and interacting signalling
proteins where multiple factors, including carcinogen exposure,
determine the precise character of somatic genes inactivated in this
particular tumour, NSCLC. In the case of BMP inactivation, there
was no apparent association of methylation silencing with tobacco
exposure. However, we identified an inverse relationship between
asbestos exposure and BMP methylation. Asbestos exposure has
been associated with cytogenetic damage in humans (Dusinska
et al, 2004). Hence, asbestos may be selecting for pathway
inactivation via large-scale genetic changes. For example, SMAD4,
the effector protein in the BMP pathway, has been identified as
mutated and deleted in lung cancer (Nagatake et al, 1996; An et al,
2002). If asbestos were associated with induction of SMAD4
inactivation in lung cancer, one would expect the inverse
association with BMP silencing that we have observed.
The balance between antigrowth and progrowth signalling that
is imperative for normal cell development and homeostasis is
reliant upon multiple feedback signalling pathways. k-ras mutation
has been described as a relatively early event in cancer (Nelson
et al, 1999) that constitutively activates the protein leading to
active growth signalling. Our data show that the BMP pathway,
which is antiproliferative, is selected for inactivation preferentially
Table 1 BMP methylation and k-ras mutation in NSCLC
BMP3B methylation BMP6 methylation Concurrent BMP3b and BMP6 methylation
NM
a M
a P-value NM
a M
a P-value NM
a M
a P-value
Overall prevalence in NSCLC (n (%)) 68 (44%) 88 (56%) 96 (60%) 63 (40%)
k-ras mutation (codon 12)
Not mutated (%) 62 (91) 69 (78) 82 (87) 49 (78) 93 (89) 30 (70)
Mutated (%) 6 (9) 19 (22) 0.03
b 12 (13) 14 (22) 0.12
b 11 (11) 13 (30) 0.003
b
aNM¼not methylated; M¼methylated.
bw
2 test.
Table 2 Logistic regression modelling of BMP methylation and k-ras mutation in NSCLC
BMP3b Meth BMP6 Meth Concurrent BMP3b and BMP6 Meth
OR
a CI OR
a CI OR
a CI
k-ras mutation 3.7 1.2, 11.4 2.9 1.1, 7.7 6.0 2.0, 17.9
Asbestos exposure 0.2 0.1, 0.6 0.3 0.1, 1.0 0.2 0.04, 0.9
Pack-years 1.002 0.992, 1.012 0.998 0.988, 1.008 1.003 0.922, 1.015
aControlling for gender and histology.
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potentiating progrowth signalling. Direct experimental investiga-
tion of this interaction in human cells and a description of the
effects of different carcinogens in different tissues upon the
disruption of this signalling are clearly indicated. This will more
precisely define the aetiologic effects of carcinogens (such as
asbestos), delineate the interlocking pathways that are dysregu-
lated in solid tumours, and potentially open avenues for
prevention and treatment of these often-fatal cancers.
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